biostudies-literatureDahi PBNCI NIH HHS943-960https://www.ebi.ac.uk/biostudies/studies/S-EPMC9062884biostudies-literatureUnknown54(7)High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT) remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM (carmustine, etoposide, cytarabine, and melphalan) and CBV (cyclophosphamide, carmustine, and etoposide) have been the most frequently used preparatory regimens for AHCT in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). This article reviews alternative combination conditioning regimens, as well as novel transplant strategies that have been developed, to reduce transplant-related toxicity while maintaining or improving efficacy. These data demonstrate that incorporation of maintenance therapy posttransplant might be the best way to improve outcomes.Bone marrow transplantationStrategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.PMC9062884P01 CA023766P30 CA008748Dahi PBLazarus HMSauter CSGiralt SAfalseStrategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT) remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM (carmustine, etoposide, cytarabine, and melphalan) and CBV (cyclophosphamide, carmustine, and etoposide) have been the most frequently used preparatory regimens for AHCT in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). This article reviews alternative combination conditioning regimens, as well as novel transplant strategies that have been developed, to reduce transplant-related toxicity while maintaining or improving efficacy. These data demonstrate that incorporation of maintenance therapy posttransplant might be the best way to improve outcomes.2019-01-01T00:00:00Z2019 Jul2025-05-18T12:05:47.397Z2025-04-05T20:40:01.847ZS-EPMC90628843039005910.1038/s41409-018-0378-z